Cellyan CEO files Form 3 with no trades

Cellyan Biotechnology Co., Ltd insider Liang Chenyu Andy, who serves as CEO and Director, filed an initial ownership report with no reported transactions.

Rhea-AI Filing Summary

Cellyan Biotechnology Co., Ltd insider Liang Chenyu Andy, who serves as CEO and Director, filed an initial ownership report with no reported transactions. The Form 3 data show zero shares bought, sold, acquired, or disposed, indicating only a baseline disclosure of status as a reporting person.

Key Figures

Buy transactions: 0 Sell transactions: 0 Net buy/sell shares: 0 shares +1 more

4 metrics

Buy transactions 0 Number of buy transactions in Form 3 transaction summary

Sell transactions 0 Number of sell transactions in Form 3 transaction summary

Net buy/sell shares 0 shares Net buy/sell direction reported as neutral

Derivative transactions 0 DerivativeTransactionCount in summary

Key Terms

CEO and Director, ten percent owner, netBuySellDirection

3 terms

CEO and Director financial

"officer_title: "CEO and Director" for Liang Chenyu Andy"

ten percent owner financial

"is_ten_percent_owner: 0 for the reporting person"

netBuySellDirection financial

"netBuySellDirection: "neutral" in transactionSummary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the reporting person in Cellyan Biotechnology (HKPD) Form 3?

The reporting person is Liang Chenyu Andy. The data identify him as both a director and an officer of Cellyan Biotechnology Co., Ltd, with the officer title listed as CEO and Director.

What positions does Liang Chenyu Andy hold at Cellyan Biotechnology (HKPD)?

Liang Chenyu Andy is listed as an officer and director. His officer title is CEO and Director, indicating he has both executive management and board responsibilities at Cellyan Biotechnology Co., Ltd.

Does the Cellyan Biotechnology (HKPD) Form 3 show any share purchases or sales?

No share purchases or sales are shown. The transaction summary reports zero buy transactions, zero sell transactions, and net buy/sell shares of 0, indicating no trading activity in this Form 3 data.

Are there any derivative security exercises reported for Cellyan Biotechnology (HKPD)?

No derivative exercises are reported. The exerciseCount and exerciseShares values are both 0, and the derivativeTransactionCount is also 0, showing no option or other derivative activity in this Form 3 snapshot.

Is Liang Chenyu Andy reported as a ten percent owner of Cellyan Biotechnology (HKPD)?

He is not reported as a ten percent owner. The ten percent owner flag for Liang Chenyu Andy is 0, meaning this Form 3 does not classify him as holding at least ten percent of the company’s shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 02:23 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Liang Chenyu Andy

(Last) (First) (Middle)

ROOM 5102, INTERNATIONAL

ARBITRATION BUILDING NANSHAN DISTRICT

(Street)

SHENZHEN CITY GUANGDONG PROVINCE 518052

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Cellyan Biotechnology Co., Ltd [ HKPD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Director

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Chenyu Liang	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)